Chemotherapy for Metastatic Tumors

Phase-Based Progress Estimates
Metastatic Tumors+1 More
Chemotherapy - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing whether a treatment called SABR, which destroys cancer cells, is better than the standard treatment for people who have a limited spread of cancer.

Eligible Conditions
  • Metastatic Tumors

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: End of years 1, 2, 3, 4, 5, and 6 (study completion)

Year 6
Overall Survival at Study Completion
Quality of Life as measured by the EuroQOL Group EQ-5D-5L questionnaire
Quality of Life as measured by the Functional Assessment of Cancer Therapy- General (FACT-G) questionnaire
Time from randomization to development of new metastatic lesions
Year 3
Overall Survival at midpoint of Study
Year 6
Progression-free Survival
Year 1
Toxicity as measured by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Standard arm
1 of 2
Stereotactic Arm
1 of 2

Active Control

Experimental Treatment

204 Total Participants · 2 Treatment Groups

Primary Treatment: Chemotherapy · No Placebo Group · Phase 3

Stereotactic ArmExperimental Group · 5 Interventions: Chemotherapy, Observation, Immunotherapy, Hormones, Stereotactic Ablative Radiotherapy · Intervention Types: Drug, Other, Drug, Drug, Radiation
Standard armActiveComparator Group · 5 Interventions: Chemotherapy, Observation, Immunotherapy, Palliative Radiation, Hormones · Intervention Types: Drug, Other, Drug, Radiation, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4
Completed Phase 4

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: end of years 1, 2, 3, 4, 5, and 6 (study completion)

Who is running the clinical trial?

British Columbia Cancer - Centre for the NorthUNKNOWN
Amsterdam University Medical Centre, VUmc SiteUNKNOWN
David PalmaLead Sponsor
London Health Sciences CentreOTHER
135 Previous Clinical Trials
47,327 Total Patients Enrolled
Beaston West of Scotland Cancer CentreUNKNOWN
Robert Olson, MDPrincipal InvestigatorBritish Columbia Cancer - Centre for the North
1 Previous Clinical Trials
399 Total Patients Enrolled
1 Trials studying Metastatic Tumors
399 Patients Enrolled for Metastatic Tumors
Stephen Harrow, MB ChBPrincipal InvestigatorBeaston West of Scotland Cancer Centre
Suresh Senan, MRCP, FRCRPrincipal InvestigatorAmsterdam University Medical Centre, VUmc Site
David Palma, MDPrincipal InvestigatorLondon Health Sciences Centre, Lawson Health Research Institute
3 Previous Clinical Trials
134 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
All sites of disease can be safely treated based on a pre-plan.
A person is willing to provide informed consent if they are able to make an informed decision about whether or not to participate in a study
You have a primary tumor that is controlled.
Histologically confirmed malignancy with metastatic disease detected on imaging.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 5th, 2021

Last Reviewed: November 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.